ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO430

Retrospective Analysis of Serum Albumin and Other Biomarkers in Chronic Hemodialysis Patients Dialyzed with the Optiflux F180NR Dialyzer

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Ficociello, Linda, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Li, Yisha, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Costanzo, Mark, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Kossmann, Robert J., Fresenius Medical Care North America, Waltham, Massachusetts, United States
Background

Optiflux® dialyzers are commonly used in US ESRD patients. Considering that low serum albumin (sALB) levels are associated with increased risk of mortality, albumin loss during hemodialysis (HD) should be minimized, especially in patients (pts) with hypoalbuminemia. A retrospective analysis was conducted to assess changes in sALB and other biomarkers in pts dialyzed with the Optiflux F180NR (OPTI).

Methods

In-center HD pts (n=284) treated with OPTI dialyzers for 6 months were analyzed. Pts maintained the same vascular access type and were without a diagnosis of liver disease or cancer. Changes in pre-dialysis (Pre-HD) labs at month 1 (M1) and month 6 (M6) were compared using paired t-tests. A sub-analysis of pts with hypoalbuminemia (sALB <3.5 mg/dL) was conducted.

Results

After 6-months of HD treatments, significant increases in mean sALB (0.07 g/dL), nPCR (0.05), and hemoglobin (0.42 g/dL) were observed with increased mean ultrafiltration volume (UFV) and adequacy (Table). A sub-analysis of 47 pts with hypoalbuminemia at M1 showed increases in sALB (0.36 g/dL) at M6 for 44 pts. Three pts had concomitant decreases in sALB (0.4 g/dL) and nPCR (0.44) during the same period.

Conclusion

During a 6-month follow-up, HD patients dialyzed with Optiflux F180NR dialyzers showed increased levels of serum albumin, nPCR, hemoglobin, ultrafiltration volume, and Kt/V.

 Month 1 (M1) MeanMonth 6 (M6) MeanDifferencep-value*
Pre-HD sAlb, in g/dL3.843.910.07< 0.0001
Normalized protein catabolic rate (nPCR), in g/kg/day1.011.060.050.002
Pre-HD Hemoglobin (Hgb), in g/dL10.6611.080.42< 0.0001
Ultrafiltration volume (UFV) in L2.572.670.100.03
spKt/V1.641.680.040.01

* from paired t-test

Funding

  • Commercial Support